Pfizer Inc. (0Q1N.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 07:12PM BST. Market open.
| Previous close | 50.58 |
| Open | 50.82 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 50.26 - 50.82 |
| 52-week range | 50.26 - 50.82 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 Oct 2022 - 04 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.30 |
- Yahoo Finance Video
UK approves COVID vaccine that targets Omicron subvariants
Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.
- Yahoo Finance
Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
- Business Wire
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
© 2022 Yahoo. All rights reserved.
